Coronavirus: US company that received $1.6bn grant announces positive results on vaccine
Vaccine among first of a handful of programmes out for US funding under Operation Warp Speed
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Novavax Inc said on Tuesday its experimental Covid-19 vaccine produced antibodies against the novel coronavirus and appears to be safe, according to initial data from a small, early-stage clinical trial.
The Maryland-based biotechnology company said its vaccine candidate, NVX-CoV2373, produced higher levels of the antibodies in healthy volunteers after two doses than those found in recovered Covid-19 patients, raising hopes for its eventual success.
The addition of its Matrix-M adjuvant, a substance designed to boost the body’s immune response, did enhance the effect of the vaccine in the study, the company said.
The Novavax vaccine is among the first of a handful of programmes out for US funding under Operation Warp Speed, the White House programme to accelerate access to vaccines and treatments that can fight the virus.
Effective vaccines and treatments are considered essential to halting a pandemic that has claimed more than 695,000 lives worldwide.
Novavax research chief Gregory Glenn told Reuters the company will start much larger late-stage clinical trials soon and could potentially glean enough data to obtain regulatory approvals as early as December.
The US government in July agreed to pay Novavax $1.6bn to help cover costs related to testing and manufacturing the vaccine, with the aim of procuring 100 million doses by January 2021.
The trial, which started in late May, tested the vaccine in 106 subjects aged 18 to 59 versus a placebo. Phase one of the study looked at the vaccine’s safety and ability to induce immune responses.
It tested 5 microgram and 25 microgram doses of the vaccine, with and without the adjuvant.
The company said the second vaccination induced greater levels of side effects such as swelling and pain at the injection site, which are not considered serious, with only one participant experiencing fever.
The Phase two portion of the study will be conducted in multiple countries, including the United States. It will gauge the vaccine’s ability to prevent infections or reduce severity of Covid-19, in addition to safety and immune response, among a broader range of volunteer
Reuters
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments